

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**AU STAR**

**奧星**

**Austar Lifesciences Limited**

**奧星生命科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6118)**

## **HIGH CONCENTRATION OF SHAREHOLDING**

This announcement is made at the request of the Stock Exchange in respect of the high concentration of the shareholding of the Company in the hands of a limited number of Shareholders as at 11 May 2021.

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares.**

This announcement is made by Austar Lifesciences Limited (“**Company**”) at the request of The Stock Exchange of Hong Kong Limited (“**Stock Exchange**”) in respect of the high concentration of the shareholding of the Company in the hands of a limited number of shareholders of the Company (“**Shareholders**”) as at 11 May 2021.

## **HIGH CONCENTRATION OF SHAREHOLDING**

The Company noted that an announcement (“**SFC Announcement**”) was published by the Securities and Futures Commission (“**SFC**”) on 27 May 2021.

As disclosed in the SFC Announcement, the SFC has recently completed an enquiry into the shareholding of the Company. The SFC’s findings suggested that, as at 11 May 2021, a group of 18 shareholders held an aggregate of 99,550,000 shares of the Company (“**Shares**”), representing 19.42% of the issued Shares. Such shareholding, together with 376,950,000 Shares (representing 73.54% of the issued Shares) held by two substantial shareholders of the Company, represented 92.96% of the issued Shares as at 11 May 2021. Therefore, only 36,082,000 Shares (representing 7.04% of the issued Shares) were held by other shareholders.

According to the SFC Announcement, as at 11 May 2021, the shareholding structure of the Company was as follows:

	<b>Number of Shares held</b> <i>(Shares)</i>	<b>% of total number of issued Shares</b> <i>(%)</i>
Mr. Ho Kwok Keung, Mars & Madam Gu Xun <i>(Note 1)</i>	339,679,000	66.27
Mr. Ho Kin Hung <i>(Note 2)</i>	37,271,000	7.27
A group of 18 shareholders	99,550,000	19.42
Other shareholders	36,082,000	7.04
	<hr/>	<hr/>
Total	<u>512,582,000</u>	<u>100.00</u>

*Note 1: Out of the 339,679,000 shares, 335,929,000 shares were held by Standard Fortune Holdings Limited and 3,750,000 shares were held by Honour Choice Ventures Limited. Standard Fortune Holdings Limited is wholly owned by Mr. Ho Kwok Keung, Mars, the Chairman and Chief Executive Officer of the Company. Honour Choice Ventures Limited is wholly owned by Madam Gu Xun, the spouse of Mr. Ho Kwok Keung, Mars. According to Part XV of the Securities & Futures Ordinance, Mr. Ho Kwok Keung, Mars and Madam Gu Xun were both deemed to be interested in the 339,679,000 shares.*

*Note 2: The 37,271,000 shares were held by True Worth Global Limited, which is wholly owned by Mr. Ho Kin Hung, an Executive Director of the Company.*

The SFC Announcement also states that share price of the Company closed between HK\$3.18 and HK\$3.73 during 4 August 2020 to 23 December 2020, with an average daily turnover of 186,398 Shares (HK\$643,038). From 24 December 2020 to 11 May 2021, the closing price of the Shares increased 141.1% from HK\$3.60 on 23 December 2020 to HK\$8.68 on 11 May 2021, while the average daily turnover rose to 616,771 Shares (HK\$3,618,217).

It was further stated in the SFC Announcement that during the period from 23 December 2020 to 11 May 2021, the Company made the following announcements (“**Announcements**”), among others:

- On 22 January 2021, the Company announced a positive profit alert that it expected to record a profit attributable to the owners of the Company in the range of RMB30 million to RMB40 million for the year ended 31 December 2020, as compared to the profit attributable to the owners of the Company of RMB8.1 million for the year ended 31 December 2019.

- On 15 February 2021, the Company announced the disposal of its entire 60% interest in PALL-AUSTAR Lifesciences Limited at an aggregate consideration of US\$34,500,000 (equivalent to approximately RMB223,139,100). The Company expected to recognize a gain of approximately RMB160 million from the disposal.
- On 26 March 2021, the Company announced the annual results for the year ended 31 December 2020, which recorded a profit attributable to the owners of the Company of RMB33.1 million, representing an increase of 309.1% from the profit attributable to the owners of the Company of RMB8.1 million for the year ended 31 December 2019.

As at 26 May 2021, the Shares closed at HK\$9.66, which was 168.3% higher than the closing price of HK\$3.60 on 23 December 2020.

The information above is extracted from the SFC Announcement and the board (“**Board**”) of directors (“**Directors**”) of the Company has not independently verified such information. Accordingly, the Board is not in a position to comment on the accuracy of the above information except for (i) the shareholdings held by Standard Fortune Holdings Limited, Honour Choice Ventures Limited and True Worth Global Limited based on the latest available disclosure of interests notices filed pursuant to Part XV of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong); and (ii) facts relating to the Announcements. Please refer to the SFC Announcement for further details.

## **PUBLIC FLOAT**

Based on the information available and to the Directors’ best knowledge after making all reasonable enquiries, the Directors confirm that not less than 25% of the issued Shares were held in public hands as at 11 May 2021 and the date of this announcement, and the Company has maintained a sufficient public float as required under the Rules Governing the Listing of Securities on the Stock Exchange.

**In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could fluctuate substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares. Further, as a result of high concentration of shareholding, the Company’s securities may not have a genuine market or its shareholding may have been concentrated in the hands of a few shareholders.**

On behalf of the Board  
**Austar Lifesciences Limited**  
**Ho Kwok Keung, Mars**  
*Chairman and Chief Executive Officer*

Hong Kong, 27 May 2021

*As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Ho Kwok Keung, Mars, Mr. Ho Kin Hung, Mr. Chen Yuewu and Madam Zhou Ning; one non-executive Director, namely Madam Ji Lingling; and three independent non-executive Directors, namely Mr. Cheung Lap Kei, Madam Chiu Hoi Shan and Mr. Leung Oi Kin.*